StockUS listing USDXCMNASDAQHealthcareQuality Compounder

DexCom Inc(DXCM) Stock Analysis | Healthcare

USD --+0.00%
Reward73High
Risk45Moderate
75%Data
Strong 20% profit margin · Revenue growing 13% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 31.74Bn
Reward Ratingⓘ73 High reward assessment · 75% data coverage
Top 25% of stocksView factors
Risk Ratingⓘ45 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on DXCM to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is DexCom Inc?

, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.

AI Brief Pro

The brief on DexCom Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is DexCom Inc?

, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 31.74B, and a P/E ratio of 33.5x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: High (73)

Similar stocks to compare

A short list of Medical Devices names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryMedical Devices
Beta1.477
Insider Activity
12M windowMixed
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
23,400 shares
$217k
0
9-12months
37,866 shares
$448k
118,200 shares
$1.0M